Colonis Pharma Ltd Launches First Licensed Product
Colonis Pharma Ltd, part of Quantum Pharma Plc, has entered the licensed pharmaceutical market with the launch of Aviticol™ (cholecalciferol 20 000 IU), for the treatment and prevention of vitamin D deficiency1.
The launch of Aviticol™ coincides with recent recommendations made by the National Institute for Health and Care Excellence (NICE) concerning vitamin D supplement use among at-risk groups. These recommendations highlight the need for greater public awareness of vitamin D deficiency and for vitamin D supplements containing the recommended reference nutrient intake for at-risk groups to be available on prescription and listed in the British National Formulary2.
“Vitamin D deficiency is a major public health issue in the UK and one that is attracting considerable attention at the moment. Moving into the licensed market with the launch of Aviticol™ for the treatment and prevention of vitamin D deficiency opens up many new opportunities for us,” explains Andy Scaife, Managing Director of Quantum Pharma Plc.
Aviticol™ can be prescribed in adults and children aged 12 years and over1.
1. Aviticol 20 000 IU Capsules - Summary of Product Characteristics. December 2014.
2. National Institute for Health and Care Excellence (NICE). Public Health Guidance: Vitamin D: Increasing Supplement Use Among At-Risk Groups. November 2014.
Posted by: Quantum Webmaster on 18th December 2014